Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Thromb Res. 2013 Nov;132(5):604-9. doi: 10.1016/j.thromres.2013.09.002. Epub 2013 Sep 6.
Patients with end-stage renal disease (ESRD) on maintenance haemodialysis are predisposed to bleeding and thrombotic events. Recently thrombin generation assay (TGA) has been introduced as a laboratory assessment of global haemostatic potential. We investigated the global haemostatic potential assessed by TGA in ESRD patients on haemodialysis and patients who developed vascular access thrombosis.
A total of 69 ESRD patients who underwent haemodialysis (58 stable patients and 11 vascular access thrombosis patients) were included and 33 healthy controls were included. TGA was performed on the calibrated automated thrombogram using tissue factor with/without addition of thrombomodulin or activated protein C, producing three parameters including lag time, endogenous thrombin potential (ETP) and peak thrombin.
Haemodialysis patients showed low ETP values measured by thrombin generation assay compared with the healthy controls. Interestingly, patients with vascular access thrombosis exhibited short PT and aPTT and increased resistance of coagulation inhibition to APC anticoagulant protein, reflecting hyper-coagulability. Haemodialysis patients who are taking anti-platelet agents showed decreased thrombin inhibition rate, representing antithrombotic effect of anti-platelet agents.
Whereas the haemodialysis patients showed hypo-coagulability, the patients with vascular access thrombosis exhibited hyper-coagulability. Further study is required to investigate how this haemostatic potential may be utilized to guide the physician to more effective management of haemostatic complication.
终末期肾病(ESRD)患者在维持性血液透析时易发生出血和血栓形成事件。最近,凝血酶生成试验(TGA)已被引入作为一种实验室评估整体止血潜能的方法。我们研究了 TGA 在血液透析的 ESRD 患者和发生血管通路血栓形成的患者中的整体止血潜能。
共纳入 69 名接受血液透析的 ESRD 患者(58 名稳定患者和 11 名血管通路血栓形成患者),并纳入 33 名健康对照者。使用组织因子和/或添加血栓调节蛋白或活化蛋白 C 对校准的自动化血栓图进行 TGA,产生三个参数,包括延迟时间、内源性凝血酶潜能(ETP)和最大凝血酶。
与健康对照组相比,血液透析患者的 TGA 测量的 ETP 值较低。有趣的是,血管通路血栓形成患者的 PT 和 aPTT 较短,并且对 APC 抗凝蛋白的凝血抑制阻力增加,反映出高凝状态。正在服用抗血小板药物的血液透析患者的凝血酶抑制率降低,代表抗血小板药物的抗血栓作用。
血液透析患者表现出低凝状态,而血管通路血栓形成患者则表现出高凝状态。需要进一步研究以探讨这种止血潜能如何用于指导医生更有效地管理止血并发症。